2022 Study Finds Testosterone Replacement Does Not Lead to Heart Attack Risk

Updated on:

Brief Summary

Summary: A study from 2022 dispels the myth that Testosterone Replacement Therapy does not increase the risk of heart attack 

View Sources

A recent study from June 2022 has uncovered evidence that dispels the myth that Testosterone treatment contributes to heart attacks. In the study titled “Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis,” researchers found that testosterone replacement therapy appears safe for use in the short-to-medium term to treat a condition caused by a hormonal deficiency in the body.

Testosterone Replacement Therapy is a medically-supervised treatment offered at Body RX Miami and Body RX Coral Gables for men suffering from hypogonadism. Low Testosterone and Hypogonadism can result in sexual dysfunction, added visceral body fat, and depression, among other debilitating symptoms.

The Myth: Testosterone Replacement Increases Risk of Heart Attacks

The Origins of The Myth

The myth is mainly based on a study involving men with known heart disease under 65 and men without symptoms 65 and older.

Nonusers had a risk of heart attack of 5 per 1,000 men followed for 1 year, while testosterone users older than 65, and those under 65 with known heart disease, had an absolute risk of 10 per 1,000 patient years. These numbers were adjusted to account for other health issues, including high blood pressure, diabetes and smoking.

Fact Check: Testosterone Replacement DOES NOT Increase Risk of Heart Attacks

In a meta-analysis, researchers looked at 17 trials involving nearly 3,500 participants, around half of which received testosterone, while half received a placebo. They found no significant increase in cardiovascular events between the testosterone and placebo groups (7.5% vs 7.2%, respectively), or mortality rate (0.4% vs 0.8%, respectively).

They found that testosterone significantly reduced some key markers of cardiovascular health, including serum total cholesterol, high-density lipoprotein (HDL), and triglycerides compared with placebo. However, there were no significant differences in serum low-density lipoprotein (LDL), blood pressure, incidence of diabetes and prostate adverse outcomes between the testosterone and placebo groups.

Dr Channa Jayasena, from Imperial College London, senior author on the paper, said: “Most men who need testosterone treatment are 50 years or older, an age at which risk factors for heart problems become more common. The majority of current guidelines say that previous studies have contradictory results about the heart safety of testosterone treatment. It is therefore likely that some men with symptomatic low testosterone are being deprived treatment due to these concerns.



En Español